Biotech Values

[jq1234]

>> By focusing on RNA and PTCT I would suggest you are acknowledging not much learned from their own trial per se.

Not at all. Based on comments on this board, you'd think Eteplirsen ph2b trial had WORST inclusion criteria among all DMD trials based on genetic mutations. The reality was just the opposite, later Drisapersen and Ataluren trials moved to the direction of eteplirsen ph2b trial inclusion criteria, NOT the other way around. It was ahead of others in narrowing down inclusion criteria with 6MWT as endpoint. Issue was the size of trial, placebo arm duration was short unlike others.